Acro Biomedical (ACBM) Net Margin (2017 - 2022)

Acro Biomedical has reported Net Margin for 6 years, with the latest figure at 1092.97% in Q4 2022.

• On a quarterly basis, Net Margin fell 71901.0% year-over-year to 1092.97% in Q4 2022; TTM through Sep 2023 was 3534.45%, a 195352.0% decrease from a year earlier, with the FY2022 full-year figure at 2410.24%, down 190241.0% from the prior year.
• Net Margin was 1092.97% for Q4 2022 at Acro Biomedical, up from 1316.18% in the prior quarter.
• The five-year high for Net Margin was 11.79% in Q1 2020, with the low at 1316.18% in Q1 2022.
• Average Net Margin over 5 years is 274.51%, with a median of 39.2% recorded in 2019.
• The sharpest annual moves came in 2018 and 2022: Net Margin tumbled 1109 bps in 2018, then slumped 125639 bps in 2022.
• Over 5 years, Net Margin stood at 5.54% in 2018, then tumbled by 608 bps to 39.2% in 2019, then soared by 130 bps to 11.79% in 2020, then tumbled by 3272 bps to 373.96% in 2021, then plunged by 192 bps to 1092.97% in 2022.
• The last three Net Margin figures came in at 1092.97% (Q4 2022), 1316.18% (Q1 2022), and 373.96% (Q4 2021), per Business Quant data.